Alignment Healthcare, Inc.
Get $10 bonus on your first $100 deposit for ALHC
Get $10 bonus on your first $100 deposit for ALHC
Alignment Healthcare, Inc. (ALHC) Stock Competitors & Peer Comparison
See (ALHC) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Healthcare Plans Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ALHC | $18.67 | -0.48% | 3.8B | -169.73 | -$0.11 | N/A |
| UNH | $281.36 | +1.48% | 255.4B | 21.27 | $13.23 | +3.14% |
| ANTM | $482.58 | +2.71% | 114.6B | 18.99 | $25.41 | +1.00% |
| CVS | $73.28 | -0.29% | 93.2B | 52.71 | $1.39 | +3.62% |
| CI | $275.69 | +2.10% | 73.6B | 12.44 | $22.17 | +2.21% |
| ELV | $302.61 | +0.62% | 66.8B | 12.01 | $25.20 | +2.24% |
| HUM | $182.65 | +2.71% | 22B | 18.59 | $9.83 | +1.93% |
| CNC | $35.40 | +0.83% | 17.4B | -2.62 | -$13.53 | N/A |
| MOH | $143.36 | +2.86% | 7.4B | 16.07 | $8.92 | N/A |
| OSCR | $12.76 | +7.05% | 3.3B | -7.55 | -$1.69 | N/A |
Stock Comparison
ALHC vs UNH Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, UNH has a market cap of 255.4B. Regarding current trading prices, ALHC is priced at $18.67, while UNH trades at $281.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas UNH's P/E ratio is 21.27. In terms of profitability, ALHC's ROE is -0.00%, compared to UNH's ROE of +0.13%. Regarding short-term risk, ALHC is less volatile compared to UNH. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check UNH's competition here
ALHC vs ANTM Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, ANTM has a market cap of 114.6B. Regarding current trading prices, ALHC is priced at $18.67, while ANTM trades at $482.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas ANTM's P/E ratio is 18.99. In terms of profitability, ALHC's ROE is -0.00%, compared to ANTM's ROE of +0.13%. Regarding short-term risk, ALHC is less volatile compared to ANTM. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check ANTM's competition here
ALHC vs CVS Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, CVS has a market cap of 93.2B. Regarding current trading prices, ALHC is priced at $18.67, while CVS trades at $73.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas CVS's P/E ratio is 52.71. In terms of profitability, ALHC's ROE is -0.00%, compared to CVS's ROE of +0.02%. Regarding short-term risk, ALHC is less volatile compared to CVS. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CVS's competition here
ALHC vs CI Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, CI has a market cap of 73.6B. Regarding current trading prices, ALHC is priced at $18.67, while CI trades at $275.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas CI's P/E ratio is 12.44. In terms of profitability, ALHC's ROE is -0.00%, compared to CI's ROE of +0.15%. Regarding short-term risk, ALHC is less volatile compared to CI. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CI's competition here
ALHC vs ELV Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, ELV has a market cap of 66.8B. Regarding current trading prices, ALHC is priced at $18.67, while ELV trades at $302.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas ELV's P/E ratio is 12.01. In terms of profitability, ALHC's ROE is -0.00%, compared to ELV's ROE of +0.13%. Regarding short-term risk, ALHC is less volatile compared to ELV. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check ELV's competition here
ALHC vs HUM Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, HUM has a market cap of 22B. Regarding current trading prices, ALHC is priced at $18.67, while HUM trades at $182.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas HUM's P/E ratio is 18.59. In terms of profitability, ALHC's ROE is -0.00%, compared to HUM's ROE of +0.07%. Regarding short-term risk, ALHC is less volatile compared to HUM. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check HUM's competition here
ALHC vs CNC Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, CNC has a market cap of 17.4B. Regarding current trading prices, ALHC is priced at $18.67, while CNC trades at $35.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas CNC's P/E ratio is -2.62. In terms of profitability, ALHC's ROE is -0.00%, compared to CNC's ROE of -0.28%. Regarding short-term risk, ALHC is more volatile compared to CNC. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check CNC's competition here
ALHC vs MOH Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, MOH has a market cap of 7.4B. Regarding current trading prices, ALHC is priced at $18.67, while MOH trades at $143.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas MOH's P/E ratio is 16.07. In terms of profitability, ALHC's ROE is -0.00%, compared to MOH's ROE of +0.11%. Regarding short-term risk, ALHC is less volatile compared to MOH. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check MOH's competition here
ALHC vs OSCR Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, OSCR has a market cap of 3.3B. Regarding current trading prices, ALHC is priced at $18.67, while OSCR trades at $12.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas OSCR's P/E ratio is -7.55. In terms of profitability, ALHC's ROE is -0.00%, compared to OSCR's ROE of -0.39%. Regarding short-term risk, ALHC is less volatile compared to OSCR. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check OSCR's competition here
ALHC vs CLOV Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, CLOV has a market cap of 957.4M. Regarding current trading prices, ALHC is priced at $18.67, while CLOV trades at $1.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas CLOV's P/E ratio is -11.00. In terms of profitability, ALHC's ROE is -0.00%, compared to CLOV's ROE of -0.26%. Regarding short-term risk, ALHC is less volatile compared to CLOV. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CLOV's competition here
ALHC vs BHG Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, BHG has a market cap of 130.5M. Regarding current trading prices, ALHC is priced at $18.67, while BHG trades at $16.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas BHG's P/E ratio is -0.12. In terms of profitability, ALHC's ROE is -0.00%, compared to BHG's ROE of -0.70%. Regarding short-term risk, ALHC is less volatile compared to BHG. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check BHG's competition here
ALHC vs CABR Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, CABR has a market cap of 18M. Regarding current trading prices, ALHC is priced at $18.67, while CABR trades at $1.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas CABR's P/E ratio is -2.65. In terms of profitability, ALHC's ROE is -0.00%, compared to CABR's ROE of N/A. Regarding short-term risk, ALHC is less volatile compared to CABR. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check CABR's competition here
ALHC vs BMGL Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, BMGL has a market cap of 11.3M. Regarding current trading prices, ALHC is priced at $18.67, while BMGL trades at $0.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas BMGL's P/E ratio is -1.36. In terms of profitability, ALHC's ROE is -0.00%, compared to BMGL's ROE of -1.95%. Regarding short-term risk, ALHC is less volatile compared to BMGL. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check BMGL's competition here
ALHC vs MRAI Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, MRAI has a market cap of 4.2M. Regarding current trading prices, ALHC is priced at $18.67, while MRAI trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas MRAI's P/E ratio is -0.08. In terms of profitability, ALHC's ROE is -0.00%, compared to MRAI's ROE of +0.52%. Regarding short-term risk, ALHC is less volatile compared to MRAI. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check MRAI's competition here
ALHC vs NIVF Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, NIVF has a market cap of 1.2M. Regarding current trading prices, ALHC is priced at $18.67, while NIVF trades at $2.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas NIVF's P/E ratio is 0.06. In terms of profitability, ALHC's ROE is -0.00%, compared to NIVF's ROE of +1.17%. Regarding short-term risk, ALHC is less volatile compared to NIVF. This indicates potentially lower risk in terms of short-term price fluctuations for ALHC.Check NIVF's competition here
ALHC vs GTS Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, GTS has a market cap of 0. Regarding current trading prices, ALHC is priced at $18.67, while GTS trades at $35.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas GTS's P/E ratio is 10.41. In terms of profitability, ALHC's ROE is -0.00%, compared to GTS's ROE of +0.07%. Regarding short-term risk, ALHC is more volatile compared to GTS. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check GTS's competition here
ALHC vs UAM Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, UAM has a market cap of 0. Regarding current trading prices, ALHC is priced at $18.67, while UAM trades at $1.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas UAM's P/E ratio is N/A. In terms of profitability, ALHC's ROE is -0.00%, compared to UAM's ROE of +0.17%. Regarding short-term risk, ALHC is more volatile compared to UAM. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check UAM's competition here
ALHC vs AET Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, AET has a market cap of 0. Regarding current trading prices, ALHC is priced at $18.67, while AET trades at $106.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas AET's P/E ratio is N/A. In terms of profitability, ALHC's ROE is -0.00%, compared to AET's ROE of +0.11%. Regarding short-term risk, ALHC is more volatile compared to AET. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check AET's competition here
ALHC vs MGLN Comparison April 2026
ALHC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ALHC stands at 3.8B. In comparison, MGLN has a market cap of 0. Regarding current trading prices, ALHC is priced at $18.67, while MGLN trades at $94.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ALHC currently has a P/E ratio of -169.73, whereas MGLN's P/E ratio is 8.49. In terms of profitability, ALHC's ROE is -0.00%, compared to MGLN's ROE of +0.00%. Regarding short-term risk, ALHC is more volatile compared to MGLN. This indicates potentially higher risk in terms of short-term price fluctuations for ALHC.Check MGLN's competition here